Abstract
For patients who were first discovered and initially diagnosed with advanced melanoma, it is worthwhile to consider whether primary site surgery (PSS) and sentinel lymph node biopsy (SLNB) can also improve the prognosis of patients. This study aimed to assess the effect of PSS and SLNB on the prognosis of patients with advanced melanoma at first diagnosis and to evaluate whether both can improve the overall survival of patients. The survival and disease information of patients with advanced cutaneous melanoma were downloaded from the Surveillance, Epidemiology, and End Results (SEER) database. The Cox proportional hazards regression was performed to identify risk factors for overall survival (OS) and melanoma-specific survival (MSS). To reduce the possibility of bias, 1:1 propensity score matching (PSM) was used to match age, race, marital status, sex, and tumor size to AJCC stage III and IV patients. A total of 918 patients were included in the study, of which the most were white, accounting for 94.9%, and the average age was 63.9 years. There were 311 females (33.9%) and 607 males (66.1%). Most of the patients with metastasis were gathered in the nonsurgical intervention group, and a few were in the PSS group. Patients with stage III who underwent “SLNB + PSS” (HR = 0.316, 95% CI 0.038–0.801, P = 0.009), PSS (HR = 0.511, 95% CI 0.323–0.874, P = 0.013), and lymphadenectomy (HR = 0.240, 95% CI 0.009–0.853, P = 0.027) had significantly reduced risk of melanoma-specific survival. In stage IV patients, PSS significantly improved patients’ OS (HR = 0.589, 95% CI 0.351–0.987, P = 0.045) and MSS (HR = 0.507 95% CI 0.321–0.849, P = 0.025). “SLNB + PSS” significantly improved OS (HR = 0.877, 95% CI 0.414–0.935, P = 0.043) and MSS (HR = 0.717 95% CI 0.315–0.854, P = 0.019) in patients. For patients with advanced melanoma on first diagnosis, sentinel lymph node biopsy and primary site surgery can still improve patient survival.
Similar content being viewed by others
Abbreviations
- PSS:
-
Primary site surgery
- SLNB:
-
Sentinel lymph node biopsy
- SEER:
-
Surveillance, Epidemiology, and End Results database
References
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S (2018) Melanoma. Lancet 392:971–984
Eggermont AM, Spatz A, Robert C (2014) Cutaneous melanoma. Lancet 383:816–827
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109–1117
Margolin K (2012) BRAF inhibition and beyond in advanced melanoma. Lancet 380:320–322
Zhang B, Zhou YL, Chen X, Wang Z, Wang Q, Ju F, Ren S, Xu R, Xue Q, Wu Q (2019) Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma. Int Immunopharmacol 68:131–136
Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300–5309
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30
Paulson KG, Gupta D, Kim TS et al (2019) Age-specific incidence of melanoma in the United States. JAMA Dermatol
Franken MG, Leeneman B, Gheorghe M, Uyl-de Groot CA, Haanen JBAG, van Baal PHM (2019) A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. Eur J Cancer 123:58–71
Gajdos C, McCarter MD (2011) Debulking surgery in advanced melanoma. Expert Rev Anticancer Ther 11:1703–1712
Puza CJ, Bressler ES, Terando AM, Howard JH, Brown MC, Hanks B, Salama AKS, Beasley GM (2019) The emerging role of surgery for patients with advanced melanoma treated with immunotherapy. J Surg Res 236:209–215
Durham AB, Wong SL (2014) Sentinel lymph node biopsy in melanoma: controversies and current guidelines. Future Oncol 10:429–442
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ, MSLT Group (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355:1307–1317
Gipponi M, Solari N, Giovinazzo D, Queirolo P, Bertoglio S, Villa G, Gualco M, Bleidl D, Cafiero F (2014) The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma. Anticancer Res 34:3197–3203
Beasley GM, Hu Y, Youngwirth L, Scheri RP, Salama AK, Rossfeld K, Gardezi S, Agnese DM, Howard JH, Tyler DS, Slingluff CL Jr, Terando AM (2017) Sentinel lymph node biopsy for recurrent melanoma: a multicenter study. Ann Surg Oncol 24:2728–2733
Nijhuis AAG, Santos Filho I, LHJ H et al (2019) Sentinel node biopsy for melanoma patients with a local recurrence or in-transit metastasis. Ann Surg Oncol
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
All authors declare that they have no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors. It has been permitted to obtain the data from SEER database (reference number 16760-Nov2018).
Informed Consent
For this type of study, formal consent is not required.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
ESM 1
(DOCX 37 kb)
Rights and permissions
About this article
Cite this article
Xia, Y., Cao, D., Zhao, J. et al. Surgical Treatments for Advanced Cutaneous Melanoma. Indian J Surg 83, 217–223 (2021). https://doi.org/10.1007/s12262-020-02374-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12262-020-02374-w